__

Proteonomix, Inc. (PROT) Plans European Investor Road Show

-Michael Cohen, Chairman and CEO, to Visit Several European Cities to Discuss Company’s Growth Plan and Future Outlook With Investors

PROTEONOMIX, INC. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced last week that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the Proteonomix, Inc. investment opportunity to institutional investors.

Scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.

The recent contract calls for the joint venture partner to invest $5 million on or before September 10, 2010 in a Joint Venture company, XGEN Medical LLC. (”XGen”), a Nevis Island limited liability company.

For additional details about the joint venture agreement, please refer to the August 17, 2010 press release.

“Proteonomix has made great strides recently,” stated Mr. Cohen, “and we have been contacted by several European entities that have requested additional information about our proprietary stem cell activities. In recognition of the interest in Europe and the potential for additional joint venture agreements in various European countries, we recognize that it is propitious to meet with a number of the European institutional investors both to educate them on the intrinsic value of Proteonomix shares and garner interest in strategic relationships.”

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD).

http://www.proteonomix.com/

__

Medtronic Releases 2010 Corporate Citizenship Report

Medtronic, Inc. (NYSE:MDT) has released “Innovating for a Better World,” the company’s 2010 Corporate Citizenship Report. The online report, which references Global Reporting Initiative (GRI) G3 Sustainability Reporting Guidelines, is available at www.medtronic.com/2010CitizenshipReport and provides a comprehensive review of the company’s commitment to global economic, social, and environmental stewardship.

The report introduces four citizenship pillars — Global Leadership in Addressing Chronic Disease, Collaborative Culture of Innovation, Total Employee Engagement, and Progressive Environmental Stewardship — that define and guide Medtronic’s activities to achieve the greatest social and business impact.

Key fiscal year 2010 citizenship initiatives and accomplishments include:

Global Leadership in Addressing Chronic Disease

• Launch of pilot programs to expand access to cardiac therapy to patients in India.
• Launch of the Every Patient First initiative to eliminate healthcare disparity impacts in the United States.
• Total philanthropic contributions of $75.6 million to support health, education and community initiatives that address noncommunicable, chronic disease around the world.

Collaborative Culture of Innovation

• Launch of a Physician Registry, which voluntarily discloses payments made to healthcare professionals for royalties and consulting services.
• Spending $1.5 billion in research and development, with about 20 percent of that designated for new patient populations.

Total Employee Engagement

• Launch of Medtronic University, which provides learning resources to employees worldwide through an online education portal.
• Measurable reductions in the number of employees who smoke or are at-risk for cholesterol or glucose since the launch of our Total Health program.

Progressive Environmental Stewardship

• Reductions in air emissions, regulated waste, volatile organic compound emissions, energy use, CO₂ emissions, and water use (normalized to revenue) compared to 2009.
• Launch of a Global Print Policy that reduced paper consumption at our Twin Cities, Minnesota, USA locations by 37 metric tonnes and is expected to yield $6.5 million in annual savings when completed in 2011.

Medtronic, Inc., headquartered in Minneapolis, is the world’s leading medical technology company, alleviating pain, restoring health, and extending life for people with chronic disease.

www.medtronic.com

__

Data from Mipomersen Phase 3 Trial in heFH Patients Presented at ESC

Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented today at the European Society of Cardiology’s Congress 2010 in Stockholm, Sweden.

The study met its primary endpoint with a 28 percent reduction in LDL-cholesterol, compared with an increase of 5 percent for placebo (p<0.001). The trial also met all of its secondary and tertiary endpoints. Frequently observed adverse events were injection site reactions, flu-like symptoms and elevations in liver transaminases, as seen in other mipomersen studies.

This double-blind, placebo-controlled phase 3 study was designed to test the efficacy and safety of adding mipomersen to stable lipid-lowering therapy. Patients were randomized 2:1 to receive a 200 mg dose of mipomersen or placebo weekly for 26 weeks. The trial included 124 adult heFH patients at 26 sites in the United States and Canada.

All of the patients had pre-existing coronary artery disease and LDL-C levels greater than 100 mg/dL, and were taking a maximally tolerated dose of a statin, as well as additional lipid-lowering drugs in most cases. Prior to study enrollment, 78 percent of patients had previously experienced at least one cardiovascular event and 49 percent had more than one previous cardiovascular event.

One of the world’s leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 12,000 employees in locations spanning the globe and 2009 revenues of $4.5 billion. In 2010, Genzyme was named to the Fortune 500.

www.genzyme.com

__

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer

Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DoubleInStocks publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. (Read more at: http://doubleinstocks.com/disclaimer) Release of Liability: Through use of this website viewing or using, you agree to hold DoubleInStocks.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

Sign Up for our FREE Daily Stock Newsletter

DoubleInStocks would like to invite you to www.crowntradingsystems.com so you can check out the super 16 multi monitor super computer he trades on daily. If you’re looking for a multi display computer to enhance your trading then you’ll want to visit www.crowntradingsystems.com

 

 

Tags:

cardiovascular disease |  GENZ |  Genzyme |  Isis Pharmaceuticals |  Medtronic |  Michael Cohen |  NASDAQ:GENZ |  NYSE:MDT |  OTC:PROT |  PROT.OB |  Proteoderm |  Proteonomix |  StromaCel |  StromalCel